

Table S1. Supplementary clinical and laboratory data of 24 patients with influenza-associated pulmonary aspergillosis.

Case	Steroid use 0-60 days before <i>Aspergillus</i> , mg/kg/d (days)	Steroid use 0-10 days after <i>Aspergillus</i> , mg/kg/d (days)	Days from intubation to <i>Aspergillus</i> growth	Co-infection 0-7 day before <i>Aspergillus</i> growth	Days from <i>Aspergillus</i> growth to RRT antifungals	MV (days)	Outcome	
1	1.45 (6)	0.51 (4)	no intubation	no	3	n	0	alive
2	n	n	<1	no	5	y	14	alive
3	n	n	5	no	4	n	35	died
4	n	n	<1	no	3	n	21	alive
5	n	n	<1	SA BSI/PN	2	n	7	alive
6	n	n	−2	no	5	n	14	alive
7	n	n	−1	KP BSI/PN	> 5	n	35	alive
8	n	n	5	KP PN	> 5	n	23	died
9	0.44 (33)	0.67 (10)	<1	PJP	4	n	5	alive
10	n	0.65 (10)	4	KP BSI	> 5	n	38	died
11	n	n	<1	KP PN	> 5	n	7	alive
12	0.97 (5)	0.37 (10)	5	SA PN	2	n	9	alive
13	n	n	−2	no	2	y	5	alive
14	n	0.61 (8)	<1	no	0	y	7	died
15	1.21 (25)	n	<1	PM BSI	1	n	21	died
16	n	0.44 (10)	<1	PA PN	2	n	27	alive
17	0.64 (13)	0.48 (10)	<1	no	−2	n	24	died
18	n	1.0 (10)	<1	no	2	n	5	alive
19		n	5	no	2	y	13	died
20	0.16 (60)	0.48 (10)	<1	PA PN	2	y	11	died, unrelated
21	0.15 (3)	0.18 (10)	8	no	2	n	20	alive
22	n	0.59 (5)	<1	no	2	y	4	died
23	n	n	4	no	0	n	27	alive
24	0.52 (59)	1.17 (5)	3	AB PN	4	y	25	died

Abbreviations: AB, *Acinetobacter baumannii*; BSI, bloodstream infection; KP, *Klebsiella pneumoniae*; MV, mechanical ventilation; PA, *Pseudomonas aeruginosa*; PM, *Proteus mirabilis*; PN, pneumonia; PJP, *Pneumocystis jirovecii* pneumonia; RRT, renal replacement therapy; SA, *Staphylococcus aureus*.